CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Indication||Platinum-Resistant Ovarian Cancer|
|Funding Request||In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer|
|Pre Noc Submission||No|
|NOC Date||September 25, 2015|
|Manufacturer||Hoffmann-La -Roche Limited|
|Sponsor||Hoffmann-La -Roche Limited|
|Submission Date||October 29, 2015|
|Submission Deemed Complete||November 5, 2015|
|Prioritization Requested||Requested and Not Granted|
|Stakeholder Input Deadline ‡||November 12, 2015|
|Check-point meeting||December 16, 2015|
|pERC Meeting||February 18, 2016|
|Initial Recommendation Issued||March 3, 2016|
|Feedback Deadline ‡||March 17, 2016|
|pERC Reconsideration Meeting||April 21, 2016|
|Final Recommendation Issued||May 5, 2016|
|Notification to Implement Issued||May 20, 2016|
|Therapeutic Area||Platinum Resistant Ovarian Cancer|
|Recommendation Type||Reimburse with clinical criteria and/or conditions|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.